title: The art of mismanagement.
abstract: Is it possible that ImClone didn't do its homework on Erbitux's patents?
mesh_terms: D000911:Antibodies, Monoclonal / Q000191:economics; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000191:economics; D001709:Biotechnology / Q000191:economics; D000068818:Cetuximab; D004345:Drug Industry / Q000191:economics / Q000458:organization & administration*; D000077544:Panitumumab; D010330:Patents as Topic
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000077544:Panitumumab; D000068818:Cetuximab